Prostate Cancer Reports
54

Volume 6 Number 7
July 2018

.

Home > Prostate Cancer Reports > Volume 6, Year 2018 > Number 7, July



CONTENTS



DIAGNOSIS
EPIDEMIOLOGY, RISK FACTORS, PREVENTION
INTEGRATIVE MEDICINE
OVERALL MANAGEMENT
PROGNOSIS
TREATMENT





DIAGNOSIS

.

Alonso O, Dos Santos G, García Fontes M, Balter H, Engler H.
68Ga-PSMA and 11C-Choline comparison using a tri-modality PET/CT-MRI (3.0 T) system with a dedicated shuttle.
Eur J Hybrid Imaging. 2018;2(1):9. doi: 10.1186/s41824-018-0027-1. Epub 2018 May 7.
Source | Abstract | Full text | Similar articles



.

Kotzerke J, Böhmer D, Schlomm T, Maurer T, Beer AJ, Schmidberger H.
[PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection].
Nuklearmedizin. 2018 Jun;57(3):69-73. doi: 10.3413/Nukmed-2018030003. Epub 2018 Jun 5. German.
Source | Abstract | Full text | Similar articles



.

Lughezzani G, Buffi NM, Lazzeri M.
Diagnostic Pathway of Patients with a Clinical Suspicion of Prostate Cancer: Does One Size Fit All?
Eur Urol. 2018 May 23. pii: S0302-2838(18)30361-0. doi: 10.1016/j.eururo.2018.05.013. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Muehlematter UJ, Rupp NJ, Mueller J, Eberli D, Burger IA.
68Ga-PSMA PET/MR-Positive, Histopathology-Proven Prostate Cancer in a Patient With Negative Multiparametric Prostate MRI.
Clin Nucl Med. 2018 May 25. doi: 10.1097/RLU.0000000000002143. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Otti VC, Miller C, Powell RJ, Thomas RM, McGrath JS.
The diagnostic accuracy of multiparametric MRI prior to biopsy in the detection of prostate cancer.
BJU Int. 2018 May 27. doi: 10.1111/bju.14420. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Wüstemann T, Haberkorn U, Babich J, Mier W.
Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy.
Med Res Rev. 2018 May 17. doi: 10.1002/med.21508. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K, Dettmann K, Langkilde NC, Haarmark C, Fisker RV, Arp DT, Carl J, Jensen JB, Petersen LJ.
Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer.
Eur J Nucl Med Mol Imaging. 2018 Jun 6. doi: 10.1007/s00259-018-4058-4. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



EPIDEMIOLOGY, RISK FACTORS, PREVENTION

.

Lamy PJ, Trétarre B, Rebillard X, Sanchez M, Cénée S, Ménégaux F.
Family history of breast cancer increases the risk of prostate cancer: results from the EPICAP study.
Oncotarget. 2018 May 4;9(34):23661-23669. doi: 10.18632/oncotarget.25320. eCollection 2018 May 4.
Source | Abstract | Full text | Similar articles



.

Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK, Benard V, Henley SJ, Anderson RN, Fedewa S, Sherman RL, Kohler BA, Dearmon BJ, Lake AJ, Ma J, Richardson LC, Jemal A, Penberthy L.
Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
Cancer. 2018 May 22. doi: 10.1002/cncr.31549. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



INTEGRATIVE MEDICINE

.

Calastretti A, Gatti G, Lucini V, Dugnani S, Canti G, Scaglione F, Bevilacqua A.
Melatonin Analogue Antiproliferative and Cytotoxic Effects on Human Prostate Cancer Cells.
Int J Mol Sci. 2018 May 18;19(5). pii: E1505. doi: 10.3390/ijms19051505.
Source | Abstract | Full text | Similar articles



.

Wang Z, Zhang L, Wan Z, He Y, Huang H, Xiang H, Wu X, Zhang K, Liu Y, Goodin S, Du Z, Zheng X.
Atorvastatin and Caffeine in Combination Regulates Apoptosis, Migration, Invasion and Tumorspheres of Prostate Cancer Cells.
Pathol Oncol Res. 2018 May 24. doi: 10.1007/s12253-018-0415-7. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



OVERALL MANAGEMENT

.

Foroughi Moghadam MJ, Taheri S, Peiravian F.
A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer.
Iran J Pharm Res. 2018 Winter;17(Suppl):17-37.
Source | Abstract | Full text | Similar articles



.

Miyahira AK, Soule HR.
The 24th Annual Prostate Cancer Foundation scientific retreat report.
Prostate. 2018 May 15. doi: 10.1002/pros.23651. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Schostak M, König F, Bögemann M, Goebell P, Hammerer P, Machtens S, Schwentner C, Thomas C, von Amsberg G, von Rundstedt FC, Heidenreich A.
[Advanced Prostate Cancer Consensus Conference 2017 : Discussion of the recommendations for diagnosis and treatment of metastatic prostate cancer by a German panel of experts].
Der Urologe. 2018 May 28. doi: 10.1007/s00120-018-0680-9. [Epub ahead of print] German.
Source | Abstract | Full text | Similar articles



PROGNOSIS

.

Ankerst DP, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, Liss MA, Leach RJ, Freedland SJ, Kattan MW, Nam R, Haese A, Montorsi F, Boorjian SA, Cooperberg MR, Poyet C, Vertosick E, Vickers AJ.
A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.
Eur Urol. 2018 May 16. pii: S0302-2838(18)30350-6. doi: 10.1016/j.eururo.2018.05.003. [Epub ahead of print]
Source | Abstract | Full text | Similar articles | PBCG Risk Calculator



.

Gandaglia G, van den Bergh RCN, Tilki D, Fossati N, Ost P, Surcel CI, Sooriakumaran P, Tsaur I, Valerio M, Kretschmer A, Zaffuto E, Salomon L, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Ploussard G; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP).
How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
BJU Int. 2018 May 17. doi: 10.1111/bju.14391. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Klotz L.
Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer.
JAMA Oncol. 2018 May 31. doi: 10.1001/jamaoncol.2018.0748. [Epub ahead of print]
Comment on: Patel HD et al, Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group. JAMA Oncol. 2018 Jan 1.4(1):89-92. doi: 10.1001/jamaoncol.2017.1879.
Source | Abstract | Full text | Similar articles



.

Kovac E, Vertosick EA, Sjoberg DD, Vickers AJ, Stephenson AJ.
Effects of Pathologic Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in men with Clinical Low-risk Prostate Cancer.
BJU Int. 2018 May 26. doi: 10.1111/bju.14418. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Lee EK, Mui WH, Chan AW, Tung Y, Wong FC.
Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Hong Kong Med J. 2018 May 21. doi: 10.12809/hkmj176888. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Park J, Yoo S, Cho MC, Cho MH, Jeong CW, Ku JH, Kwak C, Kim HH, Jeong H.
The Impact of Pathologic Upgrading of Gleason Score 7 Prostate Cancer on the Risk of the Biochemical Recurrence after Radical Prostatectomy.
Biomed Res Int. 2018 Apr 30;2018:4510149. doi: 10.1155/2018/4510149. eCollection 2018.
Source | Abstract | Full text | Similar articles



.

Patel HD, Tosoian JJ, Carter HB, Epstein JI.
Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer-Reply.
JAMA Oncol. 2018 May 31. doi: 10.1001/jamaoncol.2018.0754. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Patel HD, Tosoian JJ, Carter HB, Epstein JI.
Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.
JAMA Oncol. 2018 Jan 1;4(1):89-92. doi: 10.1001/jamaoncol.2017.1879.
Source | Abstract | Full text | Similar articles



TREATMENT

.

Aschenbrenner DS.
FDA Approves First Treatment for Nonmetastatic, Castration-Resistant Prostate Cancer.
Am J Nurs. 2018 Jun;118(6):26. doi: 10.1097/01.NAJ.0000534848.12514.1c.
Source | Abstract | Full text | Similar articles



.

Bloom JB, Gold SA, Hale GR, Rayn KN, Sabarwal VK, Bakhutashvili I, Valera V, Turkbey B, Pinto PA, Wood BJ.
"Super-active surveillance": MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer.
Gland Surg. 2018 Apr;7(2):166-187. doi: 10.21037/gs.2018.03.06.
Source | Abstract | Full text | Similar articles



.

Cereda V, Formica V, Roselli M.
Issues and promises of bevacizumab in prostate cancer treatment.
Expert Opin Biol Ther. 2018 Jun;18(6):707-717. doi: 10.1080/14712598.2018.1479737. Epub 2018 May 30.
Source | Abstract | Full text | Similar articles



.

Donovan JL, Hamdy FC.
Time for a "Radical" Change to Active Surveillance for Prostate Cancer?
Eur Urol. 2018 May 17. pii: S0302-2838(18)30357-9. doi: 10.1016/j.eururo.2018.05.009. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelson A, Bratt O, Carlsson S, Van Hemelrijck M.
Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.
Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30176-3. doi: 10.1016/j.eururo.2018.02.026. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Koo KC, Dasgupta P.
Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.
Yonsei Med J. 2018 Jul;59(5):567-579. doi: 10.3349/ymj.2018.59.5.567.
Source | Abstract | Full text | Similar articles



.

Mahal BA, Chen MH, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.
Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality.
J Natl Compr Canc Netw. 2018 Jun;16(6):727-734. doi: 10.6004/jnccn.2018.7010.
Source | Abstract | Full text | Similar articles



.

Pesapane F, Patella F, Fumarola EM, Zanchetta E, Floridi C, Carrafiello G, Standaert C.
The prostate cancer focal therapy.
Gland Surg. 2018 Apr;7(2):89-102. doi: 10.21037/gs.2017.11.08.
Source | Abstract | Full text | Similar articles



.

Vilela RA, Navarro NF, Faria ET, Ferreira EB, Ruzza RZ, Gadia R, Guerra ENS, Reis PEDD.
Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: A systematic review.
J Med Imaging Radiat Oncol. 2018 May 28. doi: 10.1111/1754-9485.12747. [Epub ahead of print]
Source | Abstract | Full text | Similar articles